158223-16-6

Basic information

• Product Name: (S)-7-Methoxy-2-aminotetralin hydrochloride
• Synonyms: (S)-7-Methoxy-2-aminotetralin hydrochloride;2-NaphthalenaMine, 1,2,3,4-tetrahydro-7-Methoxy-, hydrochloride, (2S)-;(S)-7-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine hydrochloride;2-Naphthalenamine, 1,2,3,4-tetrahydro-7-methoxy-, hydrochloride (1:1), (2S)-
• CAS NO: 158223-16-6
• Molecular Formula: C11H15NO HCl
• Molecular Weight: 0
• Product Categories: API intermediates
• Mol File: 158223-16-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 299.6°C at 760 mmHg
• Flash Point: 139.7°C
• Appearance: /
• Vapor Pressure: 0.00118mmHg at 25°C
• CAS DataBase Reference: (S)-7-Methoxy-2-aminotetralin hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-7-Methoxy-2-aminotetralin hydrochloride(158223-16-6)
• EPA Substance Registry System: (S)-7-Methoxy-2-aminotetralin hydrochloride(158223-16-6)

Safety Data

• Hazardous Substances Data: 158223-16-6(Hazardous Substances Data)

Usage

General Description

(S)-7-Methoxy-2-aminotetralin hydrochloride is a chemical compound that belongs to the class of aminotetralin derivatives. It is a hydrochloride salt form of (S)-7-Methoxy-2-aminotetralin, which is a synthetic chemical with potential antidepressant and neuroprotective activities. (S)-7-Methoxy-2-aminotetralin hydrochloride acts as a selective serotonin 5-HT1A receptor agonist, which means it binds to and activates the serotonin receptor in the brain. This activation may lead to an increase in serotonin levels in the brain, which can have mood-regulating and antidepressant effects. Furthermore, it may also have neuroprotective effects by promoting the survival of neurons and protecting them from damage. Overall, (S)-7-Methoxy-2-aminotetralin hydrochloride has potential therapeutic applications in the treatment of depression and neurodegenerative diseases.

InChI:InChI=1/C11H15NO.ClH/c1-13-11-5-3-8-2-4-10(12)6-9(8)7-11;/h3,5,7,10H,2,4,6,12H2,1H3;1H/t10-;/m0./s1

Upstream product

• 4133-34-0 7-methoxyl-2-tetralone 
• 83343-23-1 N-benzyl-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine 

Downstream Products

• 194785-79-0 (7S)-7-amino-5,6,7,8-tetrahydronaphthalen-2-ol hydrobromide 
• 194785-79-0 7-hydroxy-1,2,3,4-tetrahydro-2-naphthylamine hydrobromide 
• 220640-10-8 (7R)-7-amino-5,6,7,8-tetrahydronaphthalen-2-ol hydrobromide 
• 194785-64-3 (-)-2-[(2S)-2-[[(2R)-2-[4-Benzyloxy-3-(2-benzyloxyethyl)-phenyl]-2-hydroxyethyl]amino]-1,2,3,4-tetrahydronaphthalen-7-yloxy]-N,N-dimethylacetamide 
• 194785-68-7 (-)-(2R)-2-[4-benzyloxy-3-(2-benzyloxyethyl)phenyl]-2-hydroxy-N-((2S)-7-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide 
• 194785-70-1 (-)-(1R)-1-[4-benzyloxy-3-(2-benzyloxyethyl)phenyl]-2-((2S)-7-hydroxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)ethanol 

Relevant articles and documents

Design and optimization of potent and orally bioavailable tetrahydronaphthalene raf inhibitors

Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.

PROCESS FOR PREPARATION OF 2-AMINOTETRALIN DERIVATIVES AND INTERMEDIATES THEREOF

The present invention is to efficiently and simply prepare an optically active 7-substituted-2-aminotetralin with industrial advantage. In the process, a 7-substituted-2-tetralone or its bisulfite adduct is reduced with a microorganism to an optically active 7-substituted-2-tetralol. Then, a sulfonyl group is introduced to the hydroxy group to form an optically active 7-substituted-2-sulfonyloxytetralin. Then, with inversion of the configuration, a nitrogen substituent is introduced using a nitrogen nucleophile to form an optically active 2,7-substituted tetralin. Furthermore, if necessary, the nitrogen substituent is converted into a non-substituted amino group. Thus, an optically active 7-substituted-2-aminotetralin or its salt is prepared.

Process for the preparation of phenylethanolaminotetralins

A process for the preparation of phenylethanolaminotetralins of formula STR1 wherein X is hydrogen, a halogen, a trifluoromethyl or a lower alkyl group and R° is hydrogen or a methyl group substituted by a carboxy or a lower carbalkoxy group, which compri